Citizens Maintains Market Outperform on Spruce Biosciences, Lowers Price Target to $150
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Citizens analyst Jonathan Wolleben maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and lowers the price target from $170 to $150.
Citizens analyst Jonathan Wolleben maintains Spruce Biosciences (NASDAQ:SPRB) with a Market Outperform and lowers the price target from $170 to $150.